Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/PO-25-00576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective.
Med Sci Monit
August 2025
Independent Laboratory of Translational Medicine, Medical University of Lublin, Lublin, Poland.
Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality, with high rates of recurrence and chemoresistance. Advances in understanding the molecular biology of EOC, particularly BRCA mutations and homologous recombination deficiency (HRD), have led to more targeted therapies. This review provides an updated summary of systemic treatments for EOC, with an emphasis on personalized therapy approaches and emerging therapeutic strategies.
View Article and Find Full Text PDFFrom Fallopian Tube to Ovarian Cancer: Understanding the Evaluation and Management of Serous Tubal Intraepithelial Carcinoma Lesions.
Curr Treat Options Oncol
September 2025
Division of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Ovarian cancer, particularly high-grade serous carcinoma (HGSC), remains a leading cause of mortality in gynecologic oncology. Emerging research identifies serous tubal intraepithelial carcinoma (STIC) as a precursor lesion in many HGSC cases, highlighting its role in ovarian cancer pathogenesis and prevention. Management of STIC is challenging, as there is only limited data available to guide clinical decision-making.
View Article and Find Full Text PDFHomologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment.
Curr Issues Mol Biol
August 2025
Department of Pathology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19121, USA.
Homologous recombination deficiency (HRD) is a pivotal biomarker in precision oncology, driving therapeutic strategies for ovarian and breast cancers through impaired DNA double-strand break repair. This narrative review synthesizes recent advances (2021-2025) in HRD's biological basis, prevalence, detection methods, and clinical implications, focusing on high-grade serous ovarian carcinoma (HGSOC; ~50% HRD prevalence) and triple-negative breast cancer (TNBC; 50-70% prevalence). HRD arises from genetic (, , ) and epigenetic alterations (e.
View Article and Find Full Text PDFBRCA testing utilization among commercially insured women with breast or ovarian cancer.
Breast Cancer Res Treat
October 2025
Office of Director, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Purpose: This report examines utilization of germline BRCA genetic testing among women with breast or ovarian cancer in the context of current clinical guidelines for testing.
Methods: Linked IQVIA commercial claims and electronic medical record data were used to analyze BRCA test utilization among women aged 18-64 years with newly diagnosed breast cancer or ovarian cancer during 2016-2021, excluding 2018. Log-binomial regression models were used to estimate prevalence ratios (PRs) comparing utilization of testing by cancer type, age group, race, and year.
Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status.
Future Oncol
August 2025
Merck Research Laboratories (MRL), Merck & Co. Inc, Rahway, NJ, USA.
Introduction: This study evaluated treatment patterns and survival among patients receiving systemic therapy for HER2- early breast cancer (eBC).
Methods: A retrospective observational cohort study was used to evaluate gBRCA testing rates; treatment patterns and survival between patients tested positive for and randomly selected patients with wildtype ).
Results: gBRCA testing rate was 8.